Keywords: novavax, vlp, flu, vaccine, enters, ph, ii
Novavax' VLP flu vaccine enters Ph II trial
Article | 29 September 2008
USA-based Novavax has started inoculating healthy volunteers in a Phase II clinical trial of its virus-like particle-based seasonal influenza vaccine.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
